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Background:  Acute  myocardial  infarction  (AMI)  is  prevalent  and  has serious  consequences  including  re-
infarction  and  death.  Cigarette  smoking  is a coronary  risk  factor  for  AMI, although  a “smoker’s  paradox”
for  AMI has been  reported  in  Western  countries.  On the  other  hand,  some  researchers  have  reported  that
smoking  is  associated  with  subacute  stent  thrombosis  (SAST)  after AMI.  However,  the  occurrence  of  this
condition  is not  well documented  in  Japan.  The  aim of  this  study  was  to  clarify how prior  smoking  status
may  affect  prognosis,  including  SAST,  in  Japanese  patients  with  AMI.
Methods:  A  total of 266  consecutive  patients  with  AMI  were  enrolled  retrospectively  in the study  if they
had  undergone  emergency  coronary  intervention  (bare  metal  stent)  within  24  h  of symptom  onset,  and
had  a  5–10  month  follow-up  examination.  The  patients  were  divided  into  three  groups  based  on  their
cigarette  smoking  status  (non-smokers,  past  smokers,  and  current  smokers).
Results: Current  smokers  were  signiﬁcantly  younger  than  the  other  two  groups,  although  their  levels  of
low density  lipoprotein-cholesterol  and  triglyceride  were  signiﬁcantly  higher.  White  blood  cell count
and  hemoglobin  level  on  admission  were  also signiﬁcantly  higher  in current  smokers  compared  with  the
other  two groups.  The  incidence  of  SAST  was  signiﬁcantly  higher  in current  smokers  than  in the  other
groups,  although  the occurrence  of  heart  failure  after  AMI  was  similar  in  the  three  groups.  On  the  other
hand,  improvement  in  left  ventricular  ejection  fraction  was  observed  in  non-smokers  and past  smokers,
but  not  in  current  smokers.  Multiple  logistic  analysis  revealed  that  current  smoking  was an  independent
risk  factor  for  SAST  (odds  ratio  5.4;  p < 0.05).  Current  smokers  were  about  ﬁve  times  more  likely to have
a  SAST  compared  with non-smokers.
Conclusions:  These  ﬁndings  indicate  that  current  cigarette  smoking  predicts  SAST  after  primary  percuta-
ion  fo
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Cigarette smoking is one of the major classical risk factors for
therosclerosis and cardiovascular disease [1,2] including acute
yocardial infarction (AMI) [3–5]. AMI  is a leading cause of death in
dults and it is therefore important to evaluate patient risk includ-
ng future adverse events in the early stages after an AMI.
Smokers who have had an AMI  have lower mortality rates
han non-smokers despite having an increased risk for coronary
rtery disease. Several studies have reported this “smoker’s para-
ox” [6–8]. In contrast, other studies have shown that patients
ho continue to smoke after an AMI  have increased mortality, and
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ational Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku,
umamoto 860-0008, Japan. Tel.: +81 96 353 6501; fax: +81 96 325 2519.
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T. Honda).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.10.007r AMI  in  Japanese  patients.
anese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
that female smokers are more likely to experience cardiovascular
complications 6 months after an AMI  than male smokers [9,10].
Although the “smoker’s paradox” associated with an AMI  has been
studied in Western countries, the condition is less well documented
in Japan.
On the other hand, it has been reported that current cigarette
smoking is a risk factor for subacute stent thrombosis (SAST) after
an AMI  in Western countries [11–13]. However this association has
also not been investigated extensively in Japan.
This study therefore examined the association between prior
smoking status and prognosis including SAST in Japanese patients
with an AMI.
MethodsStudy population
The study involved a retrospective analysis of 296 consecutive
patients who underwent percutaneous coronary intervention (PCI)
vier Ltd. All rights reserved.
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t Kumamoto Medical Center within 24 h after the onset of AMI
nd had a follow-up examination 5–10 months later. The diagno-
is of AMI  was made using the Universal Deﬁnition of Myocardial
nfarction [14]. As it is possible that differences in PCI [thrombolysis,
OBA (plain old balloon angioplasty], BMS  (bare metal stent), and
ES (drug-eluting stent)] may  inﬂuence the prognosis of patients
ith AMI, the study population only included 266 patients treated
ith a BMS. The main exclusion criteria were the presence of malig-
ant disease, severe renal failure, known hepatic disease, and the
ack of a follow-up examination. The primary endpoint was  stent
hrombosis in patients treated with a BMS.
The patients were divided into three groups according to their
rior smoking status (current smokers, past smokers, and non-
mokers). We  deﬁned current smokers as individuals who had
moked any tobacco products in the previous 12 months, including
hose who had quit within the past year. Past smokers were deﬁned
s those who had quit more than one year earlier.
Blood pressure, heart rate (HR), plasma glucose (PG), white
lood cell (WBC) count, glomerular ﬁltration rate (GFR), and
emoglobin (Hb) were measured on admission to the emergency
nit of Kumamoto Medical Center. GFR was calculated using the
bbreviated Modiﬁcation of Diet in Renal Disease Study formula
15]. Creatine phosphokinase (CK) was measured every 4–6 h after
dmission in all patients. Blood samples for measures of PG and
BC  count were obtained at the time of hospital admission. Total
holesterol (T-Cho), high-density lipoprotein cholesterol (HDL-C),
ow-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and
emoglobin A1c (HbA1c) levels were measured in the fasting state
he day after admission.
nalysis of coronary risk factors for coronary artery disease
The traditional risk factors for coronary artery disease used in
he statistical analyses were hypertension (HT), lipid proﬁles (T-
ho, HDL-C, LDL-C, and TG), current cigarette smoking habit, body
ass index (BMI), and diabetes mellitus (DM).
HT was deﬁned as a blood pressure ≥140/90 mmHg  and/or
he use of antihypertensive medication, dyslipidemia as a HDL-
 < 40 mg/dl, and/or LDL-C > 140 mg/dl, and/or TG > 150 mg/dl,
nd/or the use of antidyslipidemic medication, and DM as a fas-
ing blood glucose ≥ 126 mg/dl, and/or HbA1c ≥6.5%, or the use of
ntidiabetic medication [16].
oronary angiography and coronary intervention
Emergency coronary intervention using BMSs was  performed
n all patients. The AMI  sites were divided into two  groups (ante-
ior AMI and non-anterior AMI). A diseased coronary artery was
eﬁned as stenosis ≥75%, with the patients being divided into
wo groups (single-vessel disease and multivessel disease). Reper-
usion therapy was used at the discretion of the attending physician
nd the type of BMS  was selected by the physician (DRIVERTM,
edtronic, Minneapolis, MN,  USA; VISIONTM, Abbott, Abbott
ark, IL, USA; S-STENTTM, Biosensors International, Singapore;
ntegrityTM, Medtronic, USA; TSUNAMITM, Terumo, Tokyo, Japan;
ibertéTM, Boston Scientiﬁc, Natick, MA,  USA).ual anti-platelet therapy
All patients received aspirin (200 mg)  and were given a 300 mg
oading dose of clopidogrel before the angioplasty. Aspirin was  con-
inued indeﬁnitely, with a dose of 100 mg  daily, and clopidogrel was
ontinued for at least 1 month with a daily dose of 75 mg.ology 63 (2014) 358–364 359
Evaluation of left ventricular end-diastolic volume index and left
ventricular ejection fraction by echocardiography
All patients underwent echocardiography performed by labora-
tory technicians after admission and at follow-up. The values for
left ventricular (LV) end-diastolic volume were corrected for body
surface area and expressed as the LV end-diastolic volume index
(LVEDVI).
Subacute stent thrombosis
SAST was deﬁned according to the Academic Research Consor-
tium deﬁnition and was categorized according to the time of the
event as subacute (from 24 h to 30 days) [17].
Heart failure and major cardiovascular events
Heart failure was deﬁned as dyspnea and/or edema that
required hospitalization, accompanied by pulmonary congestion
on a chest roentgenogram, and LV dysfunction on an echocardio-
gram.
Major cardiovascular events were deﬁned as death, myocardial
infarction, or cerebrovascular events after discharge.
Target lesion revascularization
A clinically driven target lesion revascularization (TLR) proce-
dure was deﬁned as one performed because of recurrent angina
and/or documented ischemia on noninvasive tests, with >70%
diameter stenosis by quantitative coronary angiography (QCA) in
the absence of symptoms [17].
Statistical analysis
The subjects were divided into three groups according to their
prior smoking status. Differences in frequencies were analyzed
using the chi-square method. A comparison of continuous vari-
ables in the three groups was performed using a one-way analysis
of variance (ANOVA), followed by Scheffé’s procedure to compare
individual groups. Continuous variables were compared in the two
groups using a two-tailed paired t-test. Odds ratios (OR) and 95%
conﬁdence intervals (CI) for SAST were calculated using logistic
regression analysis. Differences with p < 0.05 were considered sta-
tistically signiﬁcant in all the analyses. Data were expressed as the
mean ± SD.
Results
Clinical characteristics at baseline
Current smokers were signiﬁcantly younger than non-smokers.
The percentage of males in the non-smokers group was signiﬁ-
cantly lower than in the current and past smokers groups. The
percentage of HT was lower in the current smokers group com-
pared with the other two groups. Although LDL-C and TG levels
were increased signiﬁcantly in current smokers compared with the
other two groups, the percentage of patients treated with statins
was lowest in the current smokers group (Table 1).
Clinical and angiographic characteristics of acute myocardial
infarctionThere were no differences in blood pressure or HR on admis-
sion between the three groups. Anterior AMI  was  more frequent
in current smokers compared with the other groups. However, ST-
elevation myocardial infarction (STEMI), previous MI,  preinfarction
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Table 1
Clinical characteristics of the patients at baseline.
Non-smokers Past smokers Current smokers p-Value
n  = 84 n = 79 n = 103
Age (yrs) 75 ± 8 71 ± 11 59 ± 11*,†
Male (%) 25 (29.8) 72 (91.1) 92 (89.3) <0.0001
BMI  (kg/m2) 22.8 ± 3.0 23.3 ± 3.0 24.1 ± 3.1*
Hypertension (%) 59 (70.2) 49 (62.0) 54 (52.4) 0.0445
Dyslipidemia (%) 38 (45.2) 38 (48.1) 49 (47.6) 0.925
Diabetes mellitus (%) 23 (27.4) 24 (30.4) 29 (28.2) 0.908
T-Cho (mg/dl) 191 ± 40 184 ± 39 201 ± 39†
HDL-C (mg/dl) 47 ± 13 45 ± 10 42 ± 11*
LDL-C (mg/dl) 120 ± 32 117 ± 31 133 ± 35*,†
TG (mg/dl) 107 ± 59 108 ± 51 152 ± 110*,†
Hemoglobin A1c (%) 5.9 ± 1.3 6.0 ± 1.2 6.3 ± 1.8
Previous medical treatment
ACE-I (%) 4 (4.8) 2 (2.5) 2 (1.9) 0.491
ARB  (%) 22 (26.2) 13 (16.5) 17 (16.5) 0.153
Beta-blocker (%) 1 (1.2) 5 (6.3) 3 (2.9) 0.173
Statin (%) 20 (23.8) 13 (16.5) 9 (8.7) 0.0189
BMI, body mass index; T-Cho, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; ACE-I, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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e* p < 0.05 vs non-smokers.
† p < 0.05 vs past smokers.
ngina, and coronary multi-vessel involvement were not signiﬁ-
antly different in the three groups. WBC  count and hemoglobin
evel were increased signiﬁcantly in current smokers compared
ith the other groups. There was no difference in LVEDVI and LV
jection fraction (LVEF) at baseline in the three groups. The diam-
ter of the stents implanted in the culprit lesion was  signiﬁcantly
reater in current smokers than in non-smokers (Table 2).
linical characteristics of patients at follow-up
The incidence of SAST was increased signiﬁcantly in current
mokers compared with the other two groups. The follow-up period
f this study was 197 ± 65 days. Time to SAST was 6 ± 4 days after
rimary PCI. All SASTs observed in this study were deﬁnite (stent
hrombosis category of Academic Research Consortium), and each
utcome was non-fatal AMI  [17].
able 2
linical and angiographic characteristics of acute myocardial infarction.
Non-smokers 
n  = 84 
Time from chest pain to PCI (h) 8.1 ± 7.1 
SBP  on admission (mmHg) 129 ± 31 
HR  on admission (bpm) 75 ± 22 
Previous MI  (%) 5 (6.0) 
Preinfarction angina (%) 32 (38.1) 
STEMI (%) 60 (71.4) 
Anterior MI  (%) 41 (48.8) 
Killip  > I (%) 22 (26.2) 
Coronary multi-vessel involvement (%) 35 (41.7) 
PG  on admission (mg/dl) 185 ± 82 
WBC  count on admission (/mm3) 9426 ± 3327 
GFR on admission (ml/min/1.73 m2) 72.1 ± 28.0 
Hemoglobin on admission (g/dl) 12.6 ± 1.9 
Peak CK (IU/l) 2457 ± 2509 
LVEDVI at baseline (ml/m2) 59.3 ± 14.5 
LVEF  at baseline (%) 58.9 ± 11.7 
TIMI  grade 3 after PCI (%) 66 (78.6) 
Stent  diameter at culprit lesion (mm)  2.94 ± 0.45 
Stent length implanted at culprit lesion (mm)  22 ± 9 
CI, percutaneous coronary intervention; SBP, systolic blood pressure; HR, heart rate; M
lucose;  WBC, white blood cell; GFR, glomerular ﬁltration rate; CK, creatine phosphok
jection fraction; TIMI, thrombolysis in myocardial infarction.
* p < 0.05 vs non-smokers.
† p < 0.05 vs past smokers.In this study, the incidence of SAST were 4 (3.2%) of 124
DRIVERTM stents, 3 (6.7%) of 45 VISIONTM stents, 2 (3.4%) of 58
S-STENTTM stents, 1 (6.3%) of 16 IntegrityTM stents, 0 (0%) of 17
TSUNAMITM stents, and 0 (0%) of 6 LibertéTM stents, respectively.
There was  no signiﬁcant difference for the incidence of SAST among
these stents.
There were no signiﬁcant differences in the occurrence of
heart failure. In this study, 6 major cardiovascular events (4
death, 2 myocardial infarction, and 0 cerebrovascular events) were
observed during the follow-up period. Incidence of major cardio-
vascular events in each group was 3 (3.6%) of 84 non-smokers, 1
(1.3%) of 79 past-smokers, 2 (1.9%) of 103 smokers, respectively.
There was no signiﬁcant difference with regard to major cardio-
vascular events (Table 3).
Improvement in LVEF was observed in non-smokers and past
smokers, but not in current smokers (Fig. 1).
Past smokers Current smokers p-Value
n = 79 n = 103
7.5 ± 6.9 6.4 ± 5.9
136 ± 32 136 ± 33
76 ± 26 77 ± 20
7 (8.9) 8 (7.8) 0.775
24 (30.4) 37 (35.9) 0.567
56 (70.9) 80 (77.7) 0.501
31 (39.2) 59 (57.3) 0.0542
15 (19.0) 19 (18.4) 0.376
33 (41.8) 32 (31.1) 0.218
172 ± 63 196 ± 114
9305 ± 2854 10,953 ± 3468*,†
70.5 ± 25.9 79.0 ± 29.1
13.7 ± 1.8* 14.8 ± 1.5*,†
2438 ± 2580 3112 ± 2924
57.8 ± 15.2 56.8 ± 14.7
58.6 ± 11.2 59.9 ± 10.4
60 (75.9) 83 (80.6) 0.786
3.01 ± 0.42 3.10 ± 0.44*
27 ± 17* 22 ± 8†
I,  myocardial infarction; STEMI, ST-elevation myocardial infarction; PG, plasma
inase; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular
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Table  3
Clinical characteristics of patients at follow-up.
Non-smokers Past smokers Current smokers p-Value
n  = 84 n = 79 n = 103
Subacute stent thrombosis (%) 1 (1.2) 1 (1.3) 8 (7.8) 0.0240
Time  from PCI to follow-up (day) 194 ± 77 197 ± 62 199 ± 59
CHF  during follow-up (%) 7 (8.3) 2 (2.5) 5 (4.9) 0.246
Major  cardiovascular events (%) 3 (3.6) 1 (1.3) 2 (1.9) 0.589
LVEDVI at follow-up (ml/m2) 65.0 ± 17.1 62.5 ± 14.7 62.1 ± 18.8
LVEF  at follow-up (%) 63.0 ± 11.4 62.5 ± 10.3 61.4 ± 11.5
Target  lesion revascularization (%) 14 (16.7) 22 (27.8) 25 (24.3) 0.218
Active medical treatment
Aspirin (%) 84 (100) 78 (98.7) 103 (100) 0.305
ACE-I  (%) 51 (60.7) 47 (59.5) 63 (61.2) 0.973
ARB  (%) 24 (28.6) 16 (20.3) 24 (23.3) 0.451
Beta-blocker (%) 27 (32.1) 29 (36.7) 31 (30.1) 0.636
CaCB  (%) 24 (28.6) 26 (32.9) 31 (30.1) 0.830
Nitrate (%) 15 (17.9) 18 (22.8) 17 (16.5) 0.542
Diuretics (%) 19 (22.6) 11 (13.9) 14 (13.6) 0.193
Statin  (%) 65 (77.4) 47 (59.5) 80 (77.7) 0.0111
EPA  (%) 4 (4.8) 4 (5.1) 9 (8.7) 0.460
Thiazolidindione (%) 0 (0.0) 2 (2.5) 2 (1.9) 0.372
DPP4-I (%) 4 (4.8) 3 (3.8) 8 (7.8) 0.472
Insulin therapy (%) 11 (13.1) 4 (5.1) 6 (5.8) 0.100
P ft ven
a B, calc
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bCI, percutaneous coronary intervention; CHF, congestive heart failure; LVEDVI, le
ngiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CaC
nhibitor.
ogistic analysis for the risk of SAST
Multiple logistic analysis incorporating all the clinical vari-
bles in Tables 1 and 2 showed that current smoking [odds ratio
OR) 5.35; 95% conﬁdence interval (CI) 1.00–28.5; p < 0.05] was  an
ndependent risk factor for stent thrombosis with the strongest
redictive potential for the condition (Table 4).
In 20 of 266 patients, clopidogrel was changed to cilostazol with
 daily dose 200 mg  due to side effects. However, this variance was
ig. 1. Comparisons of LVEDVI and LVEF at baseline and follow-up. LVEDVI, left ven-
ricular end-diastolic volume index; LVEF, left ventricular ejection fraction. White
ox: baseline, black box: follow-up.tricular end-diastolic volume index; LVEF, left ventricular ejection fraction; ACE-I,
ium channel blocker; EPA, eicosapentaenoic acid; DPP4-I, dipeptidyl peptidase-4
not signiﬁcantly associated with incidence of SAST (OR 1.39; 95%
CI 0.17–11.5; p = 0.76).
Discussion
We report for the ﬁrst time that current cigarette smoking
increases the risk for SAST in Japanese patients with AMI  treated
with BMSs. In addition, improvement in LVEF was not observed
in current smokers, although it was observed in past smokers and
non-smokers. However, current cigarette smoking did not exacer-
bate the occurrence of congestive heart failure during follow-up.
The incidence of SAST in this study (3.8%) was  somewhat higher
in comparison with previous reports (0.71–4.5%) [11–13,18]. First,
the regimen of dual antiplatelet therapy (aspirin plus clopidogrel)
in this study was  different from that of Ishikawa’s study (aspirin
plus ticlopidine) [18]. The difference in dual anti-platelet therapy
might be associated with the incidence of SAST, because a recent
study reported that three quarters of Japanese patients with acute
coronary syndrome (ACS) carried CYP2C19 variant alleles and the
majority had increased platelet reactivity during the early phase of
ACS after standard maintenance dose of clopidogrel [19]. Second,
the prevalence of CYP2C19 polymorphism is high in Asians com-
pared to Westerners and Caucasians [19]. The association between
the occurrence of SAST and CYP2C19 polymorphism is interest-
ing, but it might be beyond the scope of the present study. Future
research is needed for further investigation [20]. Finally, this study
excluded AMI  patients who  did not undergo the follow-up exami-
nation. This might be associated with the somewhat high incidence
of SAST.
The current smokers in the study were signiﬁcantly younger
than non- and past smokers, and were more likely to be male.
In addition, the prevalence of hypertension was  lower in current
smokers, although there was  no signiﬁcant difference in the preva-
lence of dyslipidemia and diabetes in the three groups. Previous
researchers have reported that the prevalence of smoking in males
increased over time, and that smokers were younger at presen-
tation with fewer co-morbidities than non-smokers [10]. These
ﬁndings indicate that smokers experience ACS events earlier than
non-smokers, and that smoking is an important risk factor for ACS.
The levels of HDL-C were signiﬁcantly lower, but LDL-C and TG
were signiﬁcantly higher in current smokers than non-smokers as
362 T. Honda et al. / Journal of Cardiology 63 (2014) 358–364
Table 4
Logistic analysis for the risk of subacute stent thrombosis.
Univariate model Multivariate model
OR (95% CI) p-Value OR (95% CI) p-Value
Age 0.967 (0.921–1.02) 0.175 – –
Male  3.80 (0.473–30.5) 0.209 – –
BMI  1.09 (0.886–1.33) 0.429 – –
Hypertension 0.631 (0.178–2.23) 0.475 – –
HDL-C 0.992 (0.938–1.05) 0.766 – –
LDL-C 1.01 (0.995–1.03) 0.150 – –
TG  1.00 (0.999–1.01) 0.106 – –
Hemoglobin A1c 1.26 (0.937–1.70) 0.126 – –
Previous statin therapy 0.583 (0.072–4.73) 0.613 – –
SBP  on admission 1.01 (0.985–1.02) 0.638 – –
HR  on admission 0.986 (0.954–1.02) 0.377 – –
Previous MI  3.31 (0.653–16.7) 0.149 – –
STEMI 1.45 (0.300–6.98) 0.646 – –
Preinfarction angina 1.91 (0.538–6.77) 0.317 – –
Anterior MI  1.57 (0.433–5.70) 0.492 – –
Killip class > I on admission 1.64 (0.410–6.56) 0.483 – –
Coronary multi-vessel involvement 0.703 (0.177–2.78) 0.615 – –
PG  on admission 1.00 (0.995–1.01) 0.770 – –
WBC  count on admission 1.00 (1.00–1.00) 0.671 – –
GFR  on admission 1.01 (0.992–1.04) 0.195 – –
Hemoglobin on admission 1.38 (0.952–2.00) 0.0891 1.17 (0.771–1.77) 0.463
Stent  diameter implanted at culprit lesion 0.881 (0.209–3.72) 0.863 – –
Stent length implanted at culprit lesion 1.01 (0.973–1.06) 0.519 – –
Current cigarette smoking 6.78 (1.41–32.6) 0.0169 5.35 (1.00–28.5) 0.0497
OR, odds ratio; CI, conﬁdence interval; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG,  triglyceride; SBP,
systolic  blood pressure; HR, heart rate; MI,  myocardial infarction; STEMI, ST-elevation myocardial infarction; PG, plasma glucose; WBC, white blood cell; GFR, glomerular
ﬁ
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hown in Table 1. Cigarette smoking has been reported to affect
hese lipid parameters, with studies showing that the plasma levels
f HDL-C were lower and TG higher in current smokers than in non-
mokers [21,22]. These lipid proﬁles were similar to those observed
n the “metabolic syndrome”, and suggest a mechanism by which
moking may  promote atherosclerosis. Previous reports have also
hown that the levels of inﬂammatory markers in the blood are
levated in patients with the metabolic syndrome [23–25]. A pre-
ious study showed smokers had elevated levels of inﬂammatory
arkers such as blood leukocyte count and plasma C-reactive pro-
ein level [21]. In addition, another study showed that an increased
BC count on admission after AMI  was associated with smok-
ng [26]. As we have shown in an experimental animal model
hat chronic inﬂammation accompanied by the metabolic syn-
rome may  be accelerated by myocardial ischemia-reperfusion, it
s possible that cigarette smoking may  also exacerbate myocardial
schemia-reperfusion injury and the prognosis of AMI [27]. In 978
atients with a ﬁrst myocardial infarction, Robinson et al. reported
hat the smokers had a larger infarct size as estimated by serum
K concentrations (1382 IU/l versus 1146 IU/l, p = 0.010) [28]. In the
urrent study, the WBC  count on admission was signiﬁcantly higher
n current smokers than in the other two groups. In addition, there
as a tendency that current smokers had larger infarct size com-
ared to past smokers and non-smokers, and improvement in LVEF
as not observed only in current smokers. Moreover, there is a pos-
ibility that it may  be associated with frequency of SAST in current
mokers. In this study, the prevalence of anterior MI  was  greater
n current smokers. Although a previous study demonstrated that
nterior MI  was associated with adverse events after AMI, the high
ncidence of anterior MIs  in current smokers in the present study
as not related to adverse outcomes [29].
Although there is evidence that an elevated WBC  count isssociated with a high risk of adverse events following an AMI,
he occurrence of heart failure in current smokers with a high
BC count was not frequent compared to other groups. As older
ge and anemia have been shown to be risk factors for adversecardiovascular events after AMI, the earlier onset of AMI  and
increased hemoglobin level observed in current smokers may  have
a cardioprotective effect in AMI  patients, thereby improving prog-
nosis [30,31]. Although the phenomenon of “smoker’s paradox”
may  be explained by the fact that current smokers are younger at
presentation, it is also necessary to take into account that levels
of inﬂammatory markers increase with age, despite the fact that
current smokers were signiﬁcantly younger than non-smokers.
On the other hand, the incidence of SAST was  signiﬁcantly higher
in current smokers than in the other two groups. Multiple logistic
analysis showed that current smoking was an independent risk fac-
tor for SAST (OR 5.4; p < 0.05). The increased WBC  count observed
in current smokers in the present study might appear to inﬂuence
the development of SAST through a hypercoagulable or throm-
boresistant state [32]. Another established mechanism underlying
SAST is platelet-mediated thrombosis due to arterial trauma [33].
Previous studies have shown that an increased platelet count, in
combination with elevated levels of C-reactive protein and ﬁbrino-
gen, indicated an increased propensity to thrombosis in smokers
[34,35]. In addition, current smokers in our study had elevated
LDL-C levels compared with the other two  groups. It has been
reported that an increased LDL-C level enhances platelet function
and increases the sensitivity of platelets to several naturally occur-
ring agonists [36]. As there is no other report that current smoking
increases the plasma level of LDL-C, it remains uncertain whether
this is a consistent ﬁnding. In contrast, increased platelet function
induced by current smoking in combination with elevated LDL-C
levels, may  be associated with the occurrence of AMI  and SAST.
As statins have been reported to have anti-thrombotic effects
[37,38], we carried out analyses to determine whether differences
in previous medical treatment (statins) affected the incidence of
SAST. However, in our study statin therapy administered either on
or after admission was not associated with SAST.
All of the current smokers in this study quitted smoking after
admission for AMI. We  deﬁned current smokers as individuals
who had smoked any tobacco products in the previous 12 months,
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[
[
[T. Honda et al. / Journal of
ncluding those who had quit within the past year, because past
tudies reported that smoking cessation might attenuate activa-
ion of inﬂammation and hemostasis 2–12 months later [39], and
ost inﬂammatory and hemostatic levels improved within 5 years
f smoking cessation but took over 20 years to revert to levels of
on-smokers [40]. These ﬁndings were compatible with the present
tudy showing that the risk of SAST in current smokers did not
educe immediately after smoking cessation.
The present study excluded patients treated with DESs as
he number of patients was too small to analyze the association
etween current smoking and SAST after AMI. In addition, as we
xcluded patients who did not undergo a follow-up examination,
he study did not include patients who died during hospitaliza-
ion. It therefore remains uncertain whether current smoking is
ssociated with in-hospital death.
onclusions
This study demonstrated that current cigarette smoking was  an
ndependent risk factor for SAST, although it was  not associated
ith adverse outcomes in AMI  patients. It is therefore important
o pay attention to the high-risk group for SAST, especially current
mokers after a primary PCI for AMI.
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